Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that the Company had established its new subsidiary, Eisai GesmbH (Location: Vienna, General Manager: Georg Wager, “Eisai Austria”) in Austria. Eisai Austria is a subsidiary wholly-owned by Eisai Europe Limited (Headquarters: Hatfield, UK, Chairman & CEO: Yutaka Tsuchiya, “Eisai Europe”), the European subsidiary of Eisai.

Eisai entered into the Austrian market in 2005 setting up a branch of its German subsidiary Eisai GmbH (Location: Frankfurt, Managing Director: Andreas Wiegand). The Austrian branch has been marketing Zonegran® and Inovelon® for the treatment of epilepsy, Neurobloc® for cervical dystonia, Prialt® for severe chronic pain, and also collaborating in the promotion of Aricept® for Alzheimer's Disease. It has also served as a support centre for marketing, medical and regulatory affairs for the business operations in Central and Eastern Europe.

With the establishment of a subsidiary in Austria, a subsidiary wholly-owned by Eisai Europe, Eisai will strengthen its business operations in Austria and Central and Eastern European countries in preparation for future possible business expansion in this region.

Eisai currently has ten subsidiaries in Europe with the newly established Eisai Austria. Eisai will continue to strengthen its business operations in Europe and to address the diversified needs of patients and their families, thereby improving patient value.

[Eisai Austria's Outline]

Contact:
PR Department
Eisai Co., Ltd.
+81 - (0)3 - 3817 - 5120